Preparation method of chromone amide compound for Alzheimer's disease medicine

Through the structural modification and synthesis methods of chromoketone amide compounds, the problem of toxic and side effects of existing Alzheimer's disease treatment drugs has been solved, low-toxicity and effective inhibition of acetylcholinesterase is achieved, and the safety of the drug has been improved. Drug development provides the foundation.

CN118924749APending Publication Date: 2024-11-12GUANGXI UNIV FOR NATITIES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410962299.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing Alzheimer's disease treatment drugs have toxic side effects, and although acetylcholinesterase inhibitors have certain effects, they are highly toxic, making it difficult to meet the needs of more efficient and low-toxic drugs in the future.

Method used

Using chromoketone amide compounds, the purpose of acetylcholine inhibition is achieved through structural modification, and a synthesis method is designed, including a multi-step reaction process, using specific solvents and catalysts, and the obtained compound has good inhibitory effect and low toxicity. .

Benefits of technology

It has achieved low toxicity and effective inhibition of acetylcholinesterase, improved the safety of the drug, and provided experimental basis and theoretical basis for the research and development of new chromoketone amide derivatives.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention discloses a preparation method and application of a chromone amide compound for an Alzheimer's disease medicine. The chromone amide compound is shown as any one of 1)-5): 1) N-(1-benzyl-4-methylaminopiperidine)-6-fluoro-4-oxo-4H-chromene-2-carboxylic acid 2) N-(1-benzyl-4-methylaminopiperidine)-6-fluoro-4-oxo-4H-chromene-3-carboxylic acid 3) N-(1-benzyl-4-methylaminopiperidine)-7-fluoro-4-oxo-4H-chromene-3-carboxylic acid 4) The chromone amide compound is prepared from 6-fluoro-N-4-(4-methyl piperazine) aniline-4-oxo-4H-chromene-3-carboxylic acid and 6-fluoro-N-4-(4-methyl piperazine) aniline-4-oxo-4H-chromene-2-carboxylic acid. The invention further discloses a preparation method of the chromone amide compound. The chromone amide compound is prepared from 6-fluoro-N-4-(4-methyl piperazine) aniline-4-oxo-4H-chromene-3-carboxylic acid. The compound disclosed by the invention has a relatively good acetylcholin esterase inhibiting effect, and meanwhile, more toxic and side effects can be avoided, and the medication safety is improved. The method has a good application prospect in screening of anti-senile dementia drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of pharmaceutical compounds, and specifically relates to the use of a chromone amide compound for preparing a drug for treating Alzheimer's disease and a preparation method thereof. Background Art

[0002] Alzheimer's disease is the main type of senile dementia. It has a very hidden onset and a chronic and progressive course. With the increase of age, the incidence rate increases significantly, and usually about 50% of the elderly will have AD symptoms to varying degrees.

[0003] Based on the research on the pathogenesis of AD, the US FDA has currently approved five anti-Alzheimer's drugs, four of which are acetylcholinesterase inhibitors, including donepezil, tacrine, rivastigmine and galantamine. The other drug is memantine, which acts on a different receptor than other drugs, mainly by blocking the N-methyl-D-aspartate receptor.

[0004] The early cholinergic hypothesis was used to explain the pathogenesis of AD. Studies have found that AD patients have severe loss of cholinergic neurons in the nucleus basalis of Meynert in the basal forebrain and reduced choline content in the brain. Blocking the cholinergic system can simulate symptoms similar to those of AD patients with decreased learning and memory abilities. This suggests that intervention with cholinesterase inhibitors may play a role in treating AD.

[0005] Chromone amide compounds are a class of widely existing and biologically active substances. By modifying the structures of chromone amide compounds at different positions, the purpose of acetylcholine inhibition can be achieved. It is expected that more efficient and low-toxic drugs will be developed in the future and benefit mankind. Summary of the invention

[0006] In view of the above problems, the present invention provides a chromone amide compound for preparing a drug for Alzheimer's disease, a preparation method thereof and a use thereof, wherein the compound has good safety and can avoid more toxic side effects.

[0007] In order to solve the above technical problems, the present invention adopts the following technical solutions:

[0008] The present invention provides a use of a chromone amide compound for preparing a drug for Alzheimer's disease.

[0009] Furthermore, the chromone amide compound is any one of the following:

[0010] N-(1-benzyl-4-methylaminopiperidinyl)-6-fluoro-4-oxo-4H-chromene-2-carboxylic acid, referred to as G1, has the structural formula:

[0011] N-(1-benzyl-4-methylaminopiperidinyl)-6-fluoro-4-oxo-4H-chromene-3-carboxylic acid, referred to as G2, has the structural formula:

[0012] N-(1-benzyl-4-methylaminopiperidinyl)-7-fluoro-4-oxo-4H-chromene-3-carboxylic acid, referred to as G3, has the structural formula:

[0013] 6-Fluoro-N-4-(4-methylpiperazine)aniline-4-oxo-4H-chromene-3-carboxylic acid, referred to as G4, has the structural formula:

[0014] 6-Fluoro-N-4-(4-methylpiperazine)aniline-4-oxo-4H-chromene-2-carboxylic acid, referred to as G5, has the structural formula:

[0015] The present invention also provides a method for preparing the chromone amide compounds for the above-mentioned purpose, comprising the following steps:

[0016] S1: 5-fluoro-2-hydroxyacetophenone / 4-fluoro-2-hydroxyacetophenone, diethyl oxalate and sodium ethoxide solution are mixed and refluxed. After the reaction is completed, the solvent is evaporated to dryness to obtain a solid, which is then extracted with dichloromethane, washed with glacial acetic acid, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain the first product;

[0017] S2: The first product is mixed with glacial acetic acid and concentrated sulfuric acid, and refluxed. After the reaction is completed, the mixture is cooled to room temperature; distilled water is added and allowed to stand overnight; the mixture is taken out and filtered, and placed in an oven overnight to obtain the second product;

[0018] S3: Add hydrochloric acid to the second product, reflux, and cool to room temperature after the reaction is completed; add distilled water and let stand overnight; take out the mixed solution and filter it, and place it in an oven overnight to obtain the third product;

[0019] S4: reacting the chromone-2-carboxylic acid product, benzylpiperidinamine / 4-methyl-piperazinylaniline, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and dichloromethane / N,N-dimethylformamide under nitrogen protection;

[0020] S5: After the reaction, extraction with ethyl acetate, washing with saturated brine, drying with anhydrous sodium sulfate, suction filtration, concentration and drying were performed in sequence; and chromatographic separation was performed to obtain the target products G1 and G5.

[0021] Further, the step is further, in step S1, the concentration of the sodium ethoxide solution is 20%.

[0022] Further, in step S1, the reflux temperature is 80°C and the time is 3 hours.

[0023] Further, in steps S2 and S3, the reflux temperature is 100°C and the time is 4 hours.

[0024] Further, the washing concentration of glacial acetic acid was 10%.

[0025] Further, in step S2, the volume ratio of glacial acetic acid to concentrated sulfuric acid is 100:1.

[0026] Further, the hydrochloric acid concentration in step S3 is 36%.

[0027] Further, in step S5, stirring at room temperature overnight.

[0028] S6: Mix 5-fluoro-2-hydroxyacetophenone / 4-fluoro-2-hydroxyacetophenone, N,N-dimethylformamide, and phosphorus oxychloride solution, and allow to react overnight at 0°C. After the reaction is complete, pour the mixture into ice water, and filter the solid to obtain a new first product;

[0029] S7: mixing the first product with sodium chlorite, sulfonic acid amine and dichloromethane at 0°C, and filtering after the reaction to obtain a new second product;

[0030] S8: reacting the chromone-2-carboxylic acid product, benzylpiperidinamine, 4-methyl-piperazinylaniline, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and 4-dimethylaminopyridine under nitrogen protection;

[0031] S9: After the reaction, extraction with ethyl acetate, washing with saturated brine, drying with anhydrous sodium sulfate, filtration, concentration and drying were performed in sequence; column chromatography was performed to obtain the target products G2, G3 and G4.

[0032] The present invention has the following beneficial effects:

[0033] The present invention innovatively synthesized a chromone amide compound and explored its safety, proving that it has low toxicity.

[0034] The present invention cleverly designs a method for preparing chromone amide compounds.

[0035] The compound prepared by the present invention has a good acetylcholinesterase inhibitory effect and low toxicity, thereby improving drug safety. The present invention provides an experimental basis and theoretical foundation for the research and development of new chromone amide derivatives. DETAILED DESCRIPTION

[0036] In order to facilitate a better understanding of the present invention, the following examples are used to illustrate the present invention, which are within the scope of protection of the present invention, but do not limit the scope of protection of the present invention.

[0037] Example 1

[0038] Its synthetic route is as follows: Compound G1: Compound G5:

[0039] The preparation method comprises the following steps:

[0040] Weigh 5-fluoro-2-hydroxyacetophenone / 4-fluoro-2-hydroxyacetophenone, diethyl oxalate, and 20% sodium ethoxide, reflux at 90°C for 2 hours, cool to room temperature after the reaction, and evaporate the solvent to dryness. Dissolve the obtained solid in dichloromethane, wash with 10% glacial acetic acid three times, and wash with saturated brine. After extraction and separation, dry with anhydrous sodium sulfate, filter with suction, and concentrate by rotary evaporation to obtain the first step product;

[0041] S2: The product of the first step was mixed with glacial acetic acid and concentrated sulfuric acid, refluxed at 100°C for 4 hours. After the reaction was completed, it was cooled to room temperature. An appropriate amount of distilled water was added, and the mixture was placed in a refrigerator at 4°C overnight. After filtration, a large amount of solid was present. The mixture was placed in a vacuum drying oven overnight, and the product of the second step was obtained after filtration.

[0042] S3: The product of the second step and 36% hydrochloric acid were refluxed at 130°C for 4 hours; after the reaction was completed, the mixture was cooled to room temperature; an appropriate amount of distilled water was added, and the mixture was placed in a refrigerator at 4°C overnight. After filtration, a large amount of solid was present, and the solid was vacuum dried overnight to obtain the third product;

[0043] S4: The third product, benzylpiperidinamine, 4-methyl-piperazinylaniline, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 4-dimethylaminopyridine, dichloromethane / N,N-dimethylformamide, were stirred at room temperature overnight under nitrogen protection;

[0044] S5: After the reaction, the solvent was dried by rotary evaporation, dissolved in ethyl acetate, washed with 0.1M HCl and saturated brine, and dried over anhydrous sodium sulfate; filtered and concentrated by rotary evaporation; separated by column chromatography to obtain the target product, referred to as G1 / G5.

[0045] Example 2

[0046] Its synthetic route is as follows: G2: G3: G4:

[0047] The preparation method comprises the following steps:

[0048] S1: 5-fluoro-2-hydroxyacetophenone / 4-fluoro-2-hydroxyacetophenone, N,N-dimethylformamide, and phosphorus oxychloride solution were mixed and allowed to react overnight at 0°C. After the reaction was completed, the mixture was poured into ice water, and the solvent was evaporated to dryness. The solid was dissolved in dichloromethane, washed with 10% glacial acetic acid for 3 times, washed with saturated brine, extracted and separated, dried with anhydrous sodium sulfate, filtered, and concentrated by rotary evaporation to obtain a new first-step product;

[0049] S2: Mix the first product with sodium chlorite, sulfonic acid amine and dichloromethane at 0°C. After the reaction is completed, filter and place in a vacuum drying oven overnight. After suction filtration, obtain a new second step product.

[0050] S4: Add chromone-2-carboxylic acid product, benzylpiperidinamine, 4-methyl-piperazinylaniline, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and 4-dimethylaminopyridine under nitrogen protection and stir at room temperature overnight;

[0051] S5: After the reaction, the solvent was dried by rotary evaporation, dissolved in ethyl acetate, washed with 0.1M HCl and saturated brine, and dried over anhydrous sodium sulfate; filtered and concentrated by rotary evaporation; separated by column chromatography to obtain the target product, referred to as G2 / G3 / G4.

[0052] Product G1 is a black green powder solid with a yield of 37%. 1 H NMR (400MHz, DMSO-d6) δ8.94 (d, J=8.0Hz, 1H), 7.87 (dd, J=9.2, 4.4Hz, 1H), 7.84 -7.76 (m, 1H), 7.73 (dd, J=8.3, 3.1Hz, 1H), 7.35-7.29 (m, 4H), 7.28-7.22 (m, 1H) , 6.84 (s, 1H), 3.78 (ddd, J=11.5, 7.7, 4.2Hz, 1H), 3.49 (s, 2H), 2.89-2.78 (m, 2H ), 2.04 (td, J=11.9, 2.5Hz, 2H), 1.86-1.74 (m, 2H), 1.66 (qd, J=12.1, 4.0Hz, 2H).

[0053] 13 C NMR (101MHz, DMSO) δ177.27, 158.62, 156.44, 152.03, 144.30, 139.03, 131.27, 129.20, 128.66, 127.37, 123.72, 123.46, 122.19, 110.23, 109.91, 62.47, 52.55, 47.84, 31.59.

[0054] Product G2 is a light yellow powder solid with a yield of 30%. 1 H NMR (400MHz, DMSO-d6) δ14.38-11.39 (m, 1H), 8.77-7.73 (m, 1H), 7.73-7.48 (m, 1H), 7.42-7.12 (m, 6H), 6.83 (ddd, J=10.9, 9.0, 4.8Hz, 0H), 3.81-3.56 (m , 0H), 3.53-3.45 (m, 2H), 2.78 (s, 2H), 2.10 (ddt, J=33.2, 21.8, 10.8Hz, 2H) , 1.89 (d, J = 13.9Hz, 1H), 1.81-1.69 (m, 1H), 1.64 (s, 1H), 1.54-1.38 (m, 1H).

[0055] 13 C NMR (101MHz, DMSO) δ159.10, 152.05, 138.81, 138.74, 129.30, 128.64, 127.41, 127.37, 122.24, 62.63, 62.26, 51.70, 51.53, 32.84, 31.95, 31.24.

[0056] Product G3 is a light yellow powder solid with a yield of 33%. 1 H NMR (400MHz, DMSO-d6) δ15.24-14.15 (m, 1H), 9.94 (dd, J=13.7, 7.8Hz, 0H), 8.13-7.48 (m, 2H), 7.41-7.12 (m, 5H), 6.78-6.48 (m, 2H), 6.28-5.65 (m, 1H), 3.58 (dd, J=11.3, 6.8Hz, 0H), 3.52-3.40 (m, 2H), 2.76 (d, J=11.3Hz, 2H), 2.20-1.95 (m, 2H), 1.85 (q, J=12.8Hz, 2H), 1.66-1.38 (m, 2H).

[0057] 13 C NMR (101MHz, DMSO-d6) δ190.33, 166.74, 165.41, 164.41, 155.29, 151.60, 129.31, 128.65, 127 .40, 117.40, 106.02, 104.55, 89.03, 62.59, 62.28, 51.68, 50.20, 45.39, 32.85, 31.16, 29.88.

[0058] Product G4 is a yellow powder solid with a yield of 35%. 1 H NMR (400MHz, DMSO-d6) δ13.46 (d, J = 277.7Hz, 1H), 11.17 (dd, J = 491.0, 13.3Hz, 1H), 8.36-7.84 (m, 1H), 7.79-7.43 (m, 1H), 7.29 (qt, J=6.1, 3.0Hz, 2H), 7.05-6.82 (m, 3H), 6.24 (dd, J=86.2, 9.8Hz, 1H), 3.11 (q, J=6.5, 5.8Hz, 4H), 2.44 (t, J=5.1Hz, 5H), 2.22 (s, 3H).

[0059] 13 C NMR (101MHz, DMSO) δ158.82, 158.08, 148.79, 148.61, 119.52, 118.56, 118.56, 116.75, 114.46, 91.96, 55.04, 48.69, 46.23, 40.59.

[0060] Product G5 is a black green powder solid with a yield of 32%. 1 H NMR (400MHz, DMSO-d6) δ13.45 (d, J = 281.6Hz, 1H), 7.61 (ddd, J = 79.7, 9.9, 3.3Hz, 1H), 7.33-7.24 (m, 2H), 7.14 (d, J = 8.4Hz, 1H), 6. 99-6.93 (m, 2H), 6.90 (dt, J=9.3, 4.7Hz, 1H), 6.24 (dd, J=92.1, 9.9Hz, 1H), 3.16-3.06 (m, 4H), 2.45 (t, J=5.0Hz, 5H), 2.22 (s, 3H).

[0061] 13 C NMR (101MHz, DMSO) δ201.77, 190.71, 178.25, 158.80, 158.04, 148.60, 131.83, 121.68, 11 9.46, 118.56, 117.73, 116.77, 116.09, 114.41, 91.98, 55.02, 55.00, 48.81, 48.68, 46.19.

[0062] Acetylcholinesterase inhibition test results

[0063] The following biological test examples are described to illustrate the present invention.

[0064] 1. The inhibitory activity of the compounds of the present invention can be determined by using the following assay system:

[0065] Select acetylcholinesterase and prepare it to 3U / mL, dopezil as the positive drug, and DTNB to 1mmol / L. Add 150μl of PBS, 20μl of AchE, 50μl of DTNB, 50μl of ATch, and 30μl of sample diluent to the 96-well plate in sequence. After mixing and shaking, place it at 37°C for five minutes and detect it with an enzyme marker. Measure the absorbance (A) value of each well, according to the formula: inhibition rate = (average A value of negative control group - average A value of drug administration group) / (average A value of control group - A value of blank control group) * 100%.

[0066] The results are shown in Table 1

[0067] Table 1 Acetylcholinesterase inhibition test results Compound Inhibitory activity IC50 (μmol / L) G1 0.117μmol / L G2 0.132μmol / L G3 0.189μmol / L G4 0.157μmol / L G5 0.156μmol / L P (donepezil) 0.155μmol / L

[0068] Cytotoxicity test results

[0069] The following biological test examples are described to illustrate the present invention.

[0070] Two normal cells, mouse normal liver cells AML12 and human normal liver cells L02, were selected as target cells, donepezil was used as a positive drug, and the cell survival rate was determined by CCK-8 method. 0.25% trypsin was used to digest the monolayer cultured AML12 and L02 cells, and DEME medium containing 10% fetal bovine serum was used to adjust the concentration to 1×10 5 100ul of single cell suspension was inoculated into each well of a 96-well plate.

[0071] The culture plate was placed in a CO2 incubator and cultured at 37°C, 5% CO2 saturated humidity for 24 hours. After the cells adhered to the wall, the old culture medium was aspirated, and the test drug containing 10ug / ml after the culture medium was diluted was added. Five replicate wells were set for each drug. The experiment set up a blank group and a negative control group (the blank group only contained CCK-8, and the negative control group contained cells and CCK-8). The plate was placed in a CO2 incubator and cultured at 37°C, 5% CO2 saturated humidity for 48 hours. After that, the culture medium was aspirated, and 10% CCK-8 culture medium was added to each well. The plate was placed in a CO2 incubator and cultured at 37°C, 5% CO2 saturated humidity for 1 hour. The absorbance (A) value of each well at 450nm was measured on an enzyme-linked immunosorbent assay. The inhibition rate = (average A value of the negative control group - average A value of the drug administration group) / (average A value of the control group - A value of the blank control group) * 100%. The survival rate of normal cells was calculated.

[0072] The results are shown in Table 2

[0073] Table 2 Cytotoxicity test results Compound AML12 survival rate L02 survival rate G1 95.95% 96.17% G2 97.69% 95.62% G3 98.30% 95.99% G4 98.55% 96.10% G1 96.40% 96.83% P (donepezil) 78.78% 92.31%

[0074] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and changes. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A use of a chromone amide compound for treating Alzheimer's disease.

2. Use of the chromone amide compound according to claim 1 for preparing a drug for treating Alzheimer's disease, It is characterized in that The chromone amide compound is any one of the following: N-(1-benzyl-4-methylaminopiperidinyl)-6-fluoro-4-oxo-4H-chromene-2-carboxylic acid, referred to as G1, has the structural formula: N-(1-benzyl-4-methylaminopiperidinyl)-6-fluoro-4-oxo-4H-chromene-3-carboxylic acid, referred to as G2, has the structural formula: N-(1-benzyl-4-methylaminopiperidinyl)-7-fluoro-4-oxo-4H-chromene-3-carboxylic acid, referred to as G3, has the structural formula: 6-Fluoro-N-4-(4-methylpiperazine)aniline-4-oxo-4H-chromene-3-carboxylic acid, referred to as G4, has the structural formula: 6-Fluoro-N-4-(4-methylpiperazine)aniline-4-oxo-4H-chromene-2-carboxylic acid, referred to as G5, has the structural formula:

3. A method for preparing a chromone compound for use as claimed in claim 1 or 2, It is characterized in that The following steps are involved: S1: 5-fluoro-2-hydroxyacetophenone / 4-fluoro-2-hydroxyacetophenone, diethyl oxalate and sodium ethoxide solution are mixed and refluxed. After the reaction is completed, the solvent is evaporated to dryness, and the obtained solid is then extracted, washed, dried, filtered and concentrated to obtain the first product; S2: The first product is mixed with glacial acetic acid and concentrated sulfuric acid, refluxed, and after the reaction is completed, cooled to room temperature; distilled water is added, and the mixture is allowed to stand overnight; the mixture is taken out and filtered, and the mixture is allowed to stand overnight, and the second product is obtained by filtering. S3: Add hydrochloric acid to the second product, reflux, and cool to room temperature after the reaction is completed; add distilled water and let stand overnight; take out and filter, and let stand overnight to obtain the third product; S4: reacting the third product, benzylpiperidinamine, 4-methyl-piperazinylaniline, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 4-dimethylaminopyridine, and dichloromethane / N,N-dimethylformamide; S5: After the reaction is completed, extraction, washing, drying, filtration, concentration, and drying are performed in sequence; column chromatography separation is performed to obtain the target product G1 / G5. S6: Mix 5-fluoro-2-hydroxyacetophenone / 4-fluoro-2-hydroxyacetophenone, N,N-dimethylformamide, and phosphorus oxychloride solution, and allow to react overnight at 0°C. After the reaction is complete, pour the mixture into ice water, and filter the solid to obtain a new first product; S7: mixing the first product with sodium chlorite, sulfonic acid amine and dichloromethane at 0°C, and filtering after the reaction to obtain a new second product; S8: reacting the chromone-2-carboxylic acid product, benzylpiperidinamine, 4-methyl-piperazinylaniline, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and 4-dimethylaminopyridine under nitrogen protection; S9: After the reaction is completed, extraction with ethyl acetate, washing with saturated brine, drying with anhydrous sodium sulfate, suction filtration, concentration and drying are performed in sequence; column chromatography separation is performed to obtain the target products G2, G3 and G4.

4. The method for preparing chromone compounds according to claim 3, Features: In step S1, the concentration of the sodium ethoxide solution is 20%.

5. The method for preparing chromone compounds according to claim 3, Features: In step S1, the reflux temperature is 80°C and the time is 3 hours.

6. The method for preparing chromone compounds according to claim 3, Features: In steps S2 and S3, the reflux temperature is 100° C. and the time is 4 hours.

7. The method for preparing chromone compounds according to claim 3, Features: In step S2, the volume ratio of glacial acetic acid to concentrated sulfuric acid is 100:

1.

8. The method for preparing chromone compounds according to claim 3, Features: The refrigerated standing temperature in steps S2 and S3 is 4°C.

9. The method for preparing chromone compounds according to claim 3, Features: Step S6, temperature 0°C, time 12 hours.

10. The method for preparing chromone compounds according to claim 3, Features: Step S7, temperature 0°C, time 3h.